1、White PaperPromising New Developments in Artificial Intelligence:Innovating with Generative and agentic AI to drive efficiency and quality in clinical trialsRAJNEESH PATIL,VP,Digital Innovation and Strategy,IQVIAPart 1 of a 4-part series highlighting key innovations in clinical trialsTable of conten

2、tsOverview 1How the bar was raised:ensuring safe and efficient use 2Selectivity of the training data 3Taking a multi-pronged approach to safeguarding efficiency and quality 3Curating and containerizing data 4Integrating“human-in-the-loop”4Harmonization of response 5Objectivity and context of use 5Re

3、cognizing uncertainty and knowledge gaps 5Putting principles into practice:use cases of successful utilization 6Successful utilization of a scientific chatbot in a Phase III trial 6Data review:empowering central monitors and CRAs 7Talking to your analytics:an agentic AI platform for monitoring suppo

4、rt 8Looking ahead:supporting a shared vision to improve patient lives 8About the author 9 |1OverviewAs implied by the article title Promising New Developments in Artificial Intelligence these are extraordinary times for the clinical research arena.Each year,with ever-increasing anticipation,thought

5、leaders and industry professionals speculate and debate where and how to best unlock AIs potential to help to make clinical trials more efficient and inclusive and ultimately move healthcare forward by improving site and patient experiences.Within the vast and complex clinical trial ecosystem,there

6、has been no dearth of opportunities to harness these remarkable technologies whether in design and planning,patient engagement,trial delivery,clinical monitoring,regulatory submissions,or well beyond into the commercial drug development space.Recently,however,the landscape has transformed,thanks in